LaNova Medicines Overview
- Year Founded
-
2019
- Status
-
Acquired/Merged
- Employees
-
3
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$951M
LaNova Medicines General Information
Description
Developer of pharmaceutical technology and biotechnology focusing on tumor immunity and tumor microenvironment therapy. The company is mainly engaged in the research and development of new drugs and medical devices, enabling clients to address significant unmet medical needs.
Contact Information
Website
www.lanovamedicines.com(Operating Subsidiary)
Corporate Office
- 8th Floor, Building A, Number 861 Jinxiang Road
- Pudong New Area
- Shanghai, 201203
- China
Corporate Office
- 8th Floor, Building A, Number 861 Jinxiang Road
- Pudong New Area
- Shanghai, 201203
- China
LaNova Medicines Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Merger/Acquisition | 20-Aug-2025 | $951M | Completed | Generating Revenue | ||
| 6. Later Stage VC (Series C1) | 01-Jul-2024 | Completed | Generating Revenue | |||
| 5. Early Stage VC | 12-May-2023 | Completed | Generating Revenue | |||
| 4. Early Stage VC (Series B) | 17-Feb-2022 | Completed | Clinical Trials - General | |||
| 3. Early Stage VC (Series A) | 06-Nov-2020 | Completed | Clinical Trials - General | |||
| 2. Early Stage VC | 28-Apr-2020 | Completed | Clinical Trials - General | |||
| 1. Corporate | 17-Dec-2019 | Completed | Startup |
LaNova Medicines Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
LaNova Medicines Patents
LaNova Medicines Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026228774-A1 | Bispecific antibodies to cdh17 and 4-1bb | Pending | 30-Apr-2025 | ||
| WO-2026158519-A1 | Clinical use of anti-ccr8 antibodies | Pending | 23-Jan-2025 | ||
| EP-4836989-A1 | Clinical regimens of anti-ccr8 antibodies | Pending | 02-Jan-2025 | ||
| WO-2026056954-A1 | Anti-folr1 antibodies and conjugates thereof | Pending | 12-Sep-2024 | ||
| WO-2026057016-A1 | Anti-nectin-4 antibodies and conjugates thereof | Pending | 12-Sep-2024 | C07K14/7051 |
LaNova Medicines Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
LaNova Medicines Former Investors (17)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| AstraZeneca | Corporation | Minority | ||
| BioTrack Capital | Venture Capital | Minority | ||
| China Renaissance | Investment Bank | Minority | ||
| Hangzhou Tigermed Consulting Company | Corporation | Minority | ||
| Hony Capital | PE/Buyout | Minority |
LaNova Medicines FAQs
-
When was LaNova Medicines founded?
LaNova Medicines was founded in 2019.
-
Where is LaNova Medicines headquartered?
LaNova Medicines is headquartered in Shanghai, China.
-
What is the size of LaNova Medicines?
LaNova Medicines has 3 total employees.
-
What industry is LaNova Medicines in?
LaNova Medicines’s primary industry is Drug Discovery.
-
Is LaNova Medicines a private or public company?
LaNova Medicines is a Private company.
-
What is the current valuation of LaNova Medicines?
The current valuation of LaNova Medicines is .
-
What is LaNova Medicines’s current revenue?
The current revenue for LaNova Medicines is .
-
How much funding has LaNova Medicines raised over time?
LaNova Medicines has raised $200M.
-
Who are LaNova Medicines’s investors?
AstraZeneca, BioTrack Capital, China Renaissance, Hangzhou Tigermed Consulting Company, and Hony Capital are 5 of 17 investors who have invested in LaNova Medicines.
-
When was LaNova Medicines acquired?
LaNova Medicines was acquired on 20-Aug-2025.
-
Who acquired LaNova Medicines?
LaNova Medicines was acquired by Sino Biopharmaceutical.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
